Literature DB >> 14710781

Current immunosuppressive agents: efficacy, side effects, and utilization.

Jodi M Smith1, Thomas Lajos Nemeth, Ruth A McDonald.   

Abstract

Advances in immunosuppressive therapy over the past decade have led to dramatic improvements in graft survival. With the development of new agents, the focus of the transplant community is to establish regimens that maintain excellent graft survival rates but with fewer toxicities including infection, nephrotoxicity, malignancy, and cosmetic effects. Examples include the use of steroid-free protocols and calcineurin avoidance regimens, which are currently being studied by NAPRTCS. The ultimate goal of transplant immunosuppressive therapy is the induction of tolerance. As we learn more about immune function from basic and clinical research, tolerance to allografts seems a more reachable goal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14710781     DOI: 10.1016/s0031-3955(03)00121-4

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  12 in total

Review 1.  Effects of immunosuppressive therapy on wound healing.

Authors:  Roshan Bootun
Journal:  Int Wound J       Date:  2012-02-24       Impact factor: 3.315

2.  Ultrasound-promoted synthesis and immunosuppressive activity of novel quinazoline derivatives.

Authors:  Lei Zhang; Zhe Gao; Chen Peng; Zheng-Yang Bin; Dan Zhao; Jing Wu; Qiang Xu; Jian-Xin Li
Journal:  Mol Divers       Date:  2012-08-14       Impact factor: 2.943

3.  Simultaneous Determination of Six Immunosuppressants in Human Whole Blood by HPLC-MS/MS Using a Modified QuEChERS Method.

Authors:  Min Zheng; Jianshi Song; Hua Xue; Hui Li; Kaoqi Lian
Journal:  Molecules       Date:  2022-06-25       Impact factor: 4.927

4.  Rapamycin extends life and health in C57BL/6 mice.

Authors:  Yiqiang Zhang; Alex Bokov; John Gelfond; Vanessa Soto; Yuji Ikeno; Gene Hubbard; Vivian Diaz; Lauren Sloane; Keith Maslin; Stephen Treaster; Samantha Réndon; Holly van Remmen; Walter Ward; Martin Javors; Arlan Richardson; Steven N Austad; Kathleen Fischer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-05-16       Impact factor: 6.053

5.  Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data.

Authors:  Nicholas J A Webb; Sylwester Prokurat; Karel Vondrak; Alan R Watson; David A Hughes; Stephen D Marks; Nadeem E Moghal; Maggie M Fitzpatrick; David V Milford; Moin A Saleem; Caroline A Jones; Styrbjorn Friman; Rita Van Damme-Lombaerts; Francoise Janssen; Clare Hamer; Sarah Rhodes
Journal:  Pediatr Nephrol       Date:  2008-08-08       Impact factor: 3.714

Review 6.  Calcineurin inhibitors in pediatric renal transplant recipients.

Authors:  Guido Filler
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

7.  Health Effects of Long-Term Rapamycin Treatment: The Impact on Mouse Health of Enteric Rapamycin Treatment from Four Months of Age throughout Life.

Authors:  Kathleen E Fischer; Jonathan A L Gelfond; Vanessa Y Soto; Chul Han; Shinichi Someya; Arlan Richardson; Steven N Austad
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

8.  Effectiveness of pharmacological agents for the treatment of non-infectious scleritis: a systematic review protocol.

Authors:  Sathana Ingaralingam; Saaeha Rauz; Philip I Murray; Robert J Barry
Journal:  Syst Rev       Date:  2020-03-12

9.  Antrodillin, an immunosuppressive sesquiterpenoid from higher fungus Antrodiella albocinnamomea.

Authors:  Dou-Dou Liang; Xue-Wen Yi; Han Wu; Zheng-Hui Li; Guo-Kai Wang; Gui-Guang Cheng; Tao Feng
Journal:  RSC Adv       Date:  2021-01-04       Impact factor: 3.361

10.  A Novel Derivative of (-)mycousnine Produced by the Endophytic Fungus Mycosphaerella nawae, Exhibits High and Selective Immunosuppressive Activity on T Cells.

Authors:  Li-Wei Wang; Jin-Liang Wang; Jing Chen; Jia-Jie Chen; Jia-Wei Shen; Xiao-Xiao Feng; Christian P Kubicek; Fu-Cheng Lin; Chu-Long Zhang; Feng-Yang Chen
Journal:  Front Microbiol       Date:  2017-07-05       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.